Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunovia AB ( (SE:IMMNOV) ) has shared an update.
Immunovia AB announced it will release its third-quarter 2025 results on November 26, 2025, followed by a webcast teleconference hosted by CEO Jeff Borcherding. This event will provide insights into the company’s developments and allow stakeholders to engage in a Q&A session, reflecting Immunovia’s ongoing efforts to enhance its market position in pancreatic cancer diagnostics.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to make these tests available, particularly in the USA, which is the largest market for pancreatic cancer detection.
Average Trading Volume: 9,576,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK167M
See more insights into IMMNOV stock on TipRanks’ Stock Analysis page.